Notices. Final rule
463 words·~2 min read·
/register/2003/08/28/03-21835A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 520 Oral Dosage Form New Animal Drugs; Etodolac AGENCY: Food and Drug Administration, HHS. ACTION: Final rule. SUMMARY: The Food and Drug Administration
(FDA)is amending the animal drug regulations to reflect approval of a supplemental new animal drug application
(NADA)filed by Fort Dodge Animal Health, Division of American Cyanamid Co. The supplemental NADA provides for a 500-milligram
(mg)tablet size of etodolac for oral use in dogs. DATES: This rule is effective August 28, 2003. FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855,
(301)827-7540, e-mail: *mberson@cvm.fda.gov.* SUPPLEMENTARY INFORMATION: Fort Dodge Animal Health, Division of American Cyanamid Co., P.O. Box 1339, Fort Dodge, IA 50501, filed a supplement to NADA 141-108 that provides for a 500-mg tablet size of ETOGESIC (etodolac) Tablets used for the management of pain and inflammation associated with osteoarthritis in dogs. The supplemental application is approved as of May 8, 2003, and the regulations are amended in 21 CFR 520.870 to reflect the approval. The basis of approval is discussed in the freedom of information summary. In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. FDA has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required. This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808. List of Subjects in 21 CFR Part 520 Animal drugs. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows: PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS 1. The authority citation for 21 CFR part 520 continues to read as follows: Authority: 21 U.S.C. 360b. § 520.870 [Amended] 2. Section 520.870 *Etodolac* is amended in paragraph
(a)by removing “150 or 300” and by adding in its place “150, 300, or 500”. Dated: August 13, 2003. Steven D. Vaughn, Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine. [FR Doc. 03-21835 Filed 8-27-03; 8:45 am]
Connectionstraces to 4
4 references not yet in our index
- 21 CFR 520
- 21 CFR 520.870
- 21 CFR 20
- 5 USC 801-808
Citation graph
cites case law
Notices
Final rule
Cite21 CFR 520
Cite21 CFR 520.870
Cite21 CFR 20
Cite5 USC 801-808
Cites 8Cited by 0 across 0 sources